401512-42-3Relevant articles and documents
A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers
Fray, M. Jonathan,Dickinson, Roger P.,Huggins, John P.,Occleston, Nicholas L.
, p. 3514 - 3525 (2003)
The pathology of chronic dermal ulcers is characterized by excessive proteolytic activity which degrades extracellular matrix (required for cell migration) and growth factors and their receptors. The overexpression of MMP-3 (stromelysin-1) and MMP-13 (col
Asymmetric synthesis of an MMP-3 inhibitor incorporating a 2-alkyl succinate motif
Ashcroft, Christopher P.,Challenger, Stephen,Derrick, Andrew M.,Storey, Richard,Thomson, Nicholas M.
, p. 362 - 368 (2013/09/06)
An efficient and practical synthesis is presented of the pharmaceutically active MMP-3 inhibitor UK-370,106 (1) via an olefination/catalytic asymmetric hydrogenation sequence. Commercially available 5-bromo-2-iodotoluene was converted in two steps to the
Matrix metalloprotease inhibitors
-
Example 32, (2012/04/23)
Compounds of formula (I): or pharmaceutically acceptable salts thereof, or solvates of either entity, wherein the substituents have the values described herein, are useful as matrix metalloprotease (MMP) inhibitors
